Overview
- A Nature Biotechnology substudy reported on Sept. 7, 2026 that about 42 participants in an Insilico Medicine trial showed reductions on six different aging clocks after 12 weeks of rentosertib treatment.
- Rentosertib was created by Insilico’s AI platforms to target TNIK, a kinase linked to fibrosis and the senescence‑associated secretory phenotype, and the company calls the drug 'senomorphic' because it appears to modulate senescent cell signaling rather than kill those cells.
- Earlier Phase IIa results published in Nature Medicine showed clinically notable lung function gains for IPF patients given rentosertib, a result that helped trigger the start of a larger Phase III program.
- Insilico launched a randomized, double‑blind Phase III trial in China that began enrolling in July 2026 and will test whether the earlier lung benefits and biomarker changes hold in roughly 320 patients across 47 centers.
- Scientists caution the aging‑clock findings are exploratory because the substudy was small, the clocks use varied methods (methylation, proteomics and multi‑omic models) and the results may not apply to healthy people or predict long‑term outcomes.